Brokers Set Expectations for Veru Q2 Earnings

Veru Inc. (NASDAQ:VERU) – Analysts at Canaccord Genuity Group issued their Q2 2026 earnings per share (EPS) estimates for Veru in a research note issued on Monday, May 11th. Canaccord Genuity Group analyst E. Nash forecasts that the company will earn ($0.20) per share for the quarter. The consensus estimate for Veru’s current full-year earnings is ($1.43) per share.

Veru (NASDAQ:VERU) last released its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.15. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $1.90 million.

Several other equities analysts have also weighed in on VERU. Weiss Ratings reissued a “sell (e+)” rating on shares of Veru in a report on Monday, April 20th. Wall Street Zen lowered Veru from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Veru Trading Down 0.4%

Shares of NASDAQ VERU opened at $2.26 on Thursday. The stock has a fifty day simple moving average of $2.35 and a two-hundred day simple moving average of $2.46. Veru has a 1-year low of $2.06 and a 1-year high of $7.40. The firm has a market cap of $36.27 million, a price-to-earnings ratio of -1.79 and a beta of -1.19.

Institutional Investors Weigh In On Veru

Several large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. boosted its stake in Veru by 3.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 197,876 shares of the company’s stock valued at $423,000 after buying an additional 5,708 shares during the period. Bank of America Corp DE boosted its stake in Veru by 5.5% during the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after buying an additional 9,637 shares during the period. Blair William & Co. IL boosted its stake in Veru by 26.3% during the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after buying an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in Veru during the third quarter valued at $38,000. Finally, Cassaday & Co Wealth Management LLC bought a new stake in Veru during the third quarter valued at $47,000. Institutional investors own 47.16% of the company’s stock.

Key Veru News

Here are the key news stories impacting Veru this week:

• Positive Sentiment: Veru said its Phase 2b PLATEAU trial is actively enrolling and still expected to deliver an interim analysis in early 2027, which supports progress in its key obesity program. Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
• Positive Sentiment: Second-quarter net loss improved sharply year over year, and operating expenses declined, suggesting better cost control and a smaller cash burn rate. Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
• Positive Sentiment: Cash, cash equivalents and restricted cash rose to $27.6 million from $15.8 million at the prior quarter-end, improving near-term funding flexibility. Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
• Neutral Sentiment: The company posted an adjusted quarterly loss of $0.13 per share, better than analyst expectations, but revenue was minimal and well below forecasts, limiting the earnings surprise. Veru earnings report and transcript
• Neutral Sentiment: Canaccord Genuity trimmed its Q2 2026 EPS estimate to a $0.20 loss per share, reinforcing expectations that Veru remains unprofitable while it funds clinical trials. Veru Inc Q2 2026 Earnings Call Highlights
• Negative Sentiment: Despite progress, Veru still depends heavily on the success of PLATEAU, so any setback in enrollment, endpoints, or regulatory feedback could pressure the stock. Veru Inc. Announces Active Enrollment in Phase 2b PLATEAU Study

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.